Intellia Therapeutics, Inc. (NTLA) Balance Sheet

The sequential decline in total assets, from $1.3B to $857.2M over ten quarters, reflects a consistent drawdown of cash and investments to fund R&D. Equity has correspondingly fallen from $1.0B to $727.7M, with retained earnings deepening to -$2.8B. This trajectory suggests the company is consuming its balance sheet to advance its pipeline, a common pattern for pre-commercial biotechs, but the pace of erosion warrants monitoring against clinical milestones.

The reduction in total debt from $210.2M to $73.4M over the period suggests either scheduled repayments or conversions, lowering leverage to a conservative 0.10 D/E. While this provides balance-sheet cushion, the company's operating losses of roughly $400M TTM imply that the current debt level is not a primary concern; rather, the sustainability of cash reserves is the key risk. Investors should monitor whether the company can access additional debt or equity financing on favorable terms as clinical programs advance.

The sharp decline in net PP&E from $246.7M to $101.0M over six quarters suggests either asset disposals, impairments, or a strategic shift toward external manufacturing. With no goodwill on the balance sheet, the asset base is predominantly cash and investments, indicating a virtual asset-light model. This aligns with the company's reliance on CROs and CDMOs, but the shrinking PP&E may also signal reduced internal manufacturing capacity, which could impact future scalability if commercial production is needed.

The decline in total equity from $1.0B to $727.7M, coupled with a deepening accumulated deficit, suggests that the company's equity quality is deteriorating as losses accumulate. The absence of dividends or buybacks indicates all capital is being reinvested into R&D, but the reliance on external financing to sustain operations is evident. Stock-based compensation, which totaled $31.6M in 2026Q2, further dilutes existing shareholders, though it preserves cash. Investors should assess whether future dilution will be offset by clinical success.

Despite a strong current ratio of 6.65, the absolute cash balance of $106.1M is concerning given the company's quarterly operating losses averaging over $100M. The cash position has declined from $189.2M in 2024Q4, indicating a burn rate that, if sustained, would exhaust liquidity within a year. The current ratio is inflated by the lack of near-term liabilities, but the company's ability to continue as a going concern depends on securing additional financing or achieving clinical milestones that trigger partnership payments.